The Swiss NGO Public Eye is claiming victory in the European Patent OfficeExternal link battle, but Novartis says the patent in question was only one of several it has in place on the (CAR)-T cell therapy treatment it had developed together with the University of Pennsylvania.
Public Eye says the therapy costs CHF370,000 ($376,000), which it claims amounts to “abusive” commercial exploitation. It launched its challenge to the patentExternal link, along with Médecins du Monde (Doctors of the World), earlier this year.
“This volte-face confirms that the patent should never have been granted in the first place, given that the underlying technology is not novel. It also questions the validity of other patents on Kymriah and weakens the monopoly position of the Swiss giant in future price reviews,” Public Eye statedExternal link on hearing of the patent withdrawal on Monday.
Novartis says that Kymriah is “covered by several patents” that protect the cost of the innovation it put into the cell therapy treatment – not just the one that has been withdrawn.
“Novartis and the University of Pennsylvania strongly believe in the importance of intellectual property rights as an incentive for ground-breaking innovation such as Kymriah. However, both parties agreed that the opposed patent is not critical to the continued development and marketing of Kymriah and the decision has therefore been taken to withdraw the opposed patent,” Novartis said in an emailed statement to swissinfo.ch.
Public Eye said that while Novartis’s position has been weakened, the “victory does not end the monopoly of this treatment as Kymriah is still protected by other patents.”
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Swiss watch industry calls for ‘clear solution’ with US
This content was published on
Federation of the Watch Industry calls for clear solution to tariff threat and a swift agreement between Bern and Washington.
Swiss youngsters illegally obtain alcohol in a quarter of test purchases
This content was published on
In a quarter of all alcohol test purchases last year, young people in Switzerland were able to obtain beer, wine or spirits illegally.
Swiss storm damage more frequent and more expensive
This content was published on
Storm damage has increased by 126% in the last ten years. Costs have risen by 133% in the same period, according to Helvetia Insurance.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
NGOs challenge patent monopoly of leukaemia drug
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Swiss healthcare costs expected to rise well above inflation
This content was published on
On Monday, SantésuisseExternal link outlined the main reasons for the expected increases in health insurance policies. It predicts a 6% rise in physiotherapy treatments, the same greater demand for care for the elderly and in nursing homes and 5% extra medical diagnostics being performed in laboratories. In addition, insurers expect costs to rise to a…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.